Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 7 Lymphoid 7 Myeloid 3 Genitourinary 3 Tumor-Agnostic 2 Plasma cell 2 Other solid neoplasm 2 Head & Neck 2 Gynecologic 2 CNS 2 Breast 2 Thoracic 1 Sarcoma 1 Gastrointestinal 1 Dermatologic 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1439 Fluorouracil 1319 Capecitabine 1114 Gemcitabine 1057 Leucovorin 939 Bevacizumab 847 Irinotecan 830 Cisplatin 676 Radiotherapy 560 Cetuximab 482 pembrolizumab 435 Paclitaxel 401 Drug Therapy 358 Nivolumab 350 130-nm albumin-bound paclitaxel 329 Docetaxel 290 Sorafenib 288 S 1 (combination) 279 Folfox protocol 266 Albumin-Bound Paclitaxel 263 Surgical Procedures, Operative 258 lenvatinib 222 sintilimab 218 tislelizumab 214 durvalumab 212 regorafenib 209 Magnetic Resonance Spectroscopy 205 apatinib 204 Radiosurgery 204 Neoadjuvant Therapy 190

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Fluconazole × Gastrointestinal × Clear all

NCT01686607 2024-10-21

MYCOS

Astellas Pharma Inc

40,110 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡